AbbVie Inc (ABBV)vsActuate Therapeutics, Inc. Common stock (ACTU)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
ACTU
Actuate Therapeutics, Inc. Common stock
$2.88
-0.69%
HEALTHCARE · Cap: $68.29M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ACTU
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Intrinsic value data unavailable for ACTU.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
No standout strengths identified
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 8.5x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ACTU
ACTU has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ACTU
The primary concerns for ACTU are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 20/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Actuate Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for patients with serious diseases, particularly in the oncology sector. The company is progressing its proprietary drug candidates through comprehensive clinical trials to address significant unmet medical needs, thereby enhancing patient outcomes. With a commitment to innovative therapeutic approaches, Actuate is cultivating a strong pipeline that not only aims for strategic growth but also seeks to deliver substantial value to investors, solidifying its position in the biotechnology industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?